We are live on !
Find out more
DMK
David M. Knott Portfolio holdings
AUM
$275M
Turnover
23.21%
1-Year Est. Return
59.23%
This Fund
S&P 500
This Quarter Est. Return
+3.09%
1 Year Est. Return
+59.23%
3 Year Est. Return
+80.95%
5 Year Est. Return
+223.18%
10 Year Est. Return
–
AUM
$275M
AUM Growth
-$6.14M
(-2.2%)
Cap. Flow
-$20.7M
Cap. Flow % of AUM
Cap. Flow %
-7.52%
Top 10 Holdings %
Top 10 Hldgs %
46.48%
Holding
168
New
21
Increased
21
Reduced
21
Closed
18
Avg Time Held
Equity + Options
2.4
years
Top 10 Avg Time Held
Equity + Options
2
years
Top 20 Avg Time Held
Equity + Options
1.8
years
Avg Time Held Equity only
2.4
years
Top 10 Avg Time Held Equity only
2
years
Top 20 Avg Time Held Equity only
1.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Coliseum Acquisition Corp. Class A Ordinary Share
MITA
|
+$9.6M |
| 2 |
Vulcan Infrastructure and Power
VIP
|
+$6.87M |
| 3 |
BRIV
B. Riley Principal 250 Merger Corp. Class A common stock
BRIV
|
+$3.38M |
| 4 |
Calumet Specialty Products
CLMT
|
+$2.85M |
| 5 |
HZAC
Horizon Acquisition Corporation
HZAC
|
+$2.09M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Coliseum Acquisition Corp. Unit
MITAU
|
+$14.7M |
| 2 |
PSTH
Pershing Square Tontine Holdings, Ltd.
PSTH
|
+$6.26M |
| 3 |
FS KKR Capital
FSK
|
+$4.31M |
| 4 |
FAZE
FaZe Holdings Inc. Common Stock
FAZE
|
+$3.4M |
| 5 |
KKR & Co
KKR
|
+$3.14M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 29.75% |
| 2 | Healthcare | 24.81% |
| 3 | Miscellaneous | 13.26% |
| 4 | Materials | 12.2% |
| 5 | Communication Services | 7.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
KKR & Co
KKR
$78.1B
| $3.04M | 1.11% |
50,000
-50,000
| -50% | -$3.14M |
2020 Q1
6 quarters
|
|
|
AVDL
27
DELISTED
Avadel Pharmaceuticals
AVDL
| $2.96M | 1.07% |
301,864
-3,058
| -1% | -$24.1K |
2020 Q4
3 quarters
|
|
|
GLHAW
28
DELISTED
Glass Houses Acquisition Corp. Warrant
GLHAW
| $2.88M | 1.04% |
250,000
| – | – |
2021 Q2
1 quarter
|
|
29
United Therapeutics
UTHR
$23.3B
| $2.82M | 1.03% |
15,300
| – | – |
2021 Q1
2 quarters
|
|
30
JPMorgan Chase
JPM
$886B
| $2.74M | 1% |
16,740
-1,430
| -8% | -$224K |
2013 Q2
33 quarters
|
|
31
Bristol-Myers Squibb
BMY
$120B
| $2.51M | 0.91% |
42,409
-1,000
| -2% | -$65.9K |
2017 Q1
18 quarters
|
|
32
AllianceBernstein
AB
$3.18B
| $2.5M | 0.91% |
50,500
| – | – |
2013 Q2
33 quarters
|
|
|
HZNP
33
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $2.19M | 0.8% |
20,000
-12,000
| -38% | -$1.25M |
2018 Q2
13 quarters
|
|
|
HZAC
34
DELISTED
Horizon Acquisition Corporation
HZAC
| $2.1M | 0.76% |
+210,100
| New | +$2.09M |
2021 Q3
0 quarters
|
|
|
EIGR
35
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $2.09M | 0.76% |
10,416
+864
| +9% | +$205K |
2017 Q3
16 quarters
|
|
36
DELISTED
Twelve Seas Investment Company II Warrant
TWLVW
| $1.98M | 0.72% |
171,666
| – | – |
2021 Q2
1 quarter
|
|
37
DELISTED
Priveterra Acquisition Corp. II Class A Common Stock
PMGM
| $1.97M | 0.72% |
200,000
| – | – |
2021 Q1
2 quarters
|
|
|
MSAC
38
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
| $1.95M | 0.71% |
+200,000
| New | +$1.93M |
2021 Q3
0 quarters
|
|
39
Innoviva
INVA
$1.52B
| $1.93M | 0.7% |
115,269
+67,471
| +141% | +$1.01M |
2021 Q2
1 quarter
|
|
|
ZGNX
40
DELISTED
Zogenix, Inc.
ZGNX
| $1.89M | 0.69% |
124,688
| – | – |
2020 Q1
6 quarters
|
|
41
Incyte
INCY
$23B
| $1.82M | 0.66% |
+26,475
| New | +$2.01M |
2021 Q3
0 quarters
|
|
|
FAZE
42
DELISTED
FaZe Holdings Inc. Common Stock
FAZE
| $1.72M | 0.63% |
176,963
-350,000
| -66% | -$3.4M |
2021 Q2
1 quarter
|
|
|
KAIRW
43
DELISTED
Kairos Acquisition Corp. Warrant
KAIRW
| $1.68M | 0.61% |
146,528
| – | – |
2021 Q1
2 quarters
|
|
44
TG Therapeutics
TGTX
$8.16B
| $1.65M | 0.6% |
49,592
-781
| -2% | -$24.2K |
2020 Q2
5 quarters
|
|
45
Coherus Oncology
CHRS
$148M
| $1.65M | 0.6% |
102,555
+2,900
| +3% | +$42.5K |
2017 Q2
17 quarters
|
|
46
uniQure
QURE
$1.54B
| $1.5M | 0.54% |
46,766
| – | – |
2019 Q4
7 quarters
|
|
47
Xenon Pharmaceuticals
XENE
$3.4B
| $1.44M | 0.52% |
94,488
-46,063
| -33% | -$800K |
2017 Q3
16 quarters
|
|
48
Aurinia Pharmaceuticals
AUPH
$2.19B
| $1.39M | 0.51% |
62,896
-101,944
| -62% | -$1.62M |
2020 Q1
6 quarters
|
|
|
BRIVW
49
DELISTED
B. Riley Principal 250 Merger Corp. Warrant
BRIVW
| $1.34M | 0.49% |
+116,666
| New | +$109K |
2021 Q3
0 quarters
|
|
50
Viking Therapeutics
VKTX
$3.19B
| $1.31M | 0.47% |
208,102
| – | – |
2017 Q4
15 quarters
|
|
Similar funds
FA
KCP
HCIA
ISG
TPCM
DCM
MCL
DVC
David M. Knott's Q3 2021 Portfolio in Review
As of Q3 2021, David M. Knott held 168 positions worth $275M, down 2.2% from $281M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
David M. Knott withdrew a net $20.7M in Q3 2021, closing 18 positions and reducing 21 holdings. Its most notable exit was Coliseum Acquisition Corp. Unit, an estimated $14.7M position sold in full.
By sector, the portfolio is most concentrated in Financials at 30% of assets, up from 28% a quarter earlier, followed by Healthcare and Miscellaneous.
Against the trend, David M. Knott opened a new position in Coliseum Acquisition Corp. Class A Ordinary Share worth $9.6M.
- David M. Knott's largest Q3 2021 buy was Coliseum Acquisition Corp. Class A Ordinary Share: 984,835 shares worth $9.6M.
- David M. Knott added most to Calumet Specialty Products in Q3 2021, an estimated $2.85M increase.
- David M. Knott's biggest Q3 2021 reduction was FS KKR Capital, cutting an estimated $4.31M.
- David M. Knott fully exited Coliseum Acquisition Corp. Unit in Q3 2021, selling an estimated $14.7M.
- David M. Knott's ten largest holdings make up 46% of its $275M portfolio in Q3 2021.
- David M. Knott opened 21 new positions and closed 18 in Q3 2021.
- David M. Knott's portfolio value fell 2.2% quarter-over-quarter to $275M.
Based on David M. Knott's 13F filing for Q3 2021, filed 12 Nov 2021.